Evidence map›Paper›PMID 36235245›Full record

ReviewMolecules (Basel, Switzerland)2022

Diaza-1,3-butadienes as Useful Intermediate in Heterocycles Synthesis.

Jorge Heredia-Moya, Daniel A Zurita, José Eduardo Cadena-Cruz, Christian D Alcívar-León

Abstract readReview
In one paragraph

Review in Molecules (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Editorial: Heterodienes in organic synthesis.Frontiers in chemistry · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Jorge Heredia-MoyaCenter for Biomedical Research (CENBIO), Eugenio Espejo College of Health Sciences, Universidad UTE, Quito 170527, Ecuador.ORCID 0000-0001-7620-9140
Daniel A ZuritaFacultad de Ciencias Químicas, Universidad Central del Ecuador, Francisco Viteri s/n y Gilberto Gato Sobral, Quito 170521, Ecuador.
José Eduardo Cadena-CruzFacultad de Ciencias Químicas, Universidad Central del Ecuador, Francisco Viteri s/n y Gilberto Gato Sobral, Quito 170521, Ecuador.ORCID 0000-0001-9023-7674
Christian D Alcívar-LeónFacultad de Ciencias Químicas, Universidad Central del Ecuador, Francisco Viteri s/n y Gilberto Gato Sobral, Quito 170521, Ecuador.ORCID 0000-0001-6987-3107

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Many heterocyclic compounds can be synthetized using diaza-1,3-butadienes (DADs) as key structural precursors. Isolated and in situ diaza-1,3-butadienes, produced from their respective precursors (typically imines and hydrazones) under a variety of conditions, can both react with a wide range of substrates in many kinds of reactions. Most of these reactions discussed here include nucleophilic additions, Michael-type reactions, cycloadditions, Diels-Alder, inverse electron demand Diels-Alder, and aza-Diels-Alder reactions. This review focuses on the reports during the last 10 years employing 1,2-diaza-, 1,3-diaza-, 2,3-diaza-, and 1,4-diaza-1,3-butadienes as intermediates to synthesize heterocycles such as indole, pyrazole, 1,2,3-triazole, imidazoline, pyrimidinone, pyrazoline, -lactam, and imidazolidine, among others. Fused heterocycles, such as quinazoline, isoquinoline, and dihydroquinoxaline derivatives, are also included in the review.

Indexed as

ImidazolidinesImidazolinesButadienesHydrazonesIminesIndolesIsoquinolinesLactamsPyrazolesPyrimidinonesQuinazolinesTriazoles1,3-butadieneButadienesHydrazonesImidazolidinesImidazolinesIminesIndolesIsoquinolinesLactamsPyrazolesPyrimidinonesQuinazolinesTriazolesdiaza-1,3-butadienesheterocyclessynthesis

Identifiers

PMID36235245
PMCPMC9573662

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.